1. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022;77:734–766.

2. Song WJ, Choi M, Lee DH, et al. The KAAACI/KDA evidence-based practice guidelines for chronic spontaneous urticaria in Korean adults and children: Part 1. Definition, methodology and first-line management. Allergy Asthma Immunol Res 2020;12:563–578.

3. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011;66:317–330.

4. Antia C, Baquerizo K, Korman A, Bernstein JA, Alikhan A. Urticaria: a comprehensive review: epidemiology, diagnosis, and work-up. J Am Acad Dermatol 2018;79:599–614.

5. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol 2010;35:869–873.

6. Chu CY, Cho YT, Jiang JH, Lin EI, Tang CH. Epidemiology and comorbidities of patients with chronic urticaria in Taiwan : a nationwide population-based study. J Dermatol Sci 2017;88:192–198.

7. Stepaniuk P, Kan M, Kanani A. Natural history, prognostic factors and patient perceived response to treatment in chronic spontaneous urticaria. Allergy Asthma Clin Immunol 2020;16:63.

8. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol 2010;125:676–682.

9. Kaplan AP. Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res 2012;4:326–331.

10. Curto-Barredo L, Gimenez-Arnau AM. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamine. G Ital Dermatol Venereol 2019;154:444–456.

11. Choi JH, Lee DH, Song WJ, et al. The KAAACI/KDA evidence-based practice guidelines for chronic spontaneous urticaria in Korean adults and children. Part 2. Management of H1-antihistamine-refractory chronic urticaria. Allergy Asthma Immunol Res 2020;12:750–770.

12. Barbosa F, Freitas J, Barbosa A. Chronic idiopathic urticaria and anxiety symptoms. J Health Psychol 2011;16:1038–1047.

13. Choi GS, Nam YH, Park CS, et al. Anxiety, depression, and stress in Korean patients with chronic urticaria. Korean J Intern Med 2020;35:1507–1516.

14. Maurer M, Abuzakouk M, Berard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017;72:2005–2016.

15. Maurer M, Staubach P, Raap U, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it’s worse than we thought: first results of the multicenter real-life AWARE study. Clin Exp Allergy 2017;47:684–692.

16. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018;73:1393–1414.

17. Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score: validity, reliability, and responsiveness. J Allergy Clin Immunol Pract 2018;6:1185–1190.

18. Ye YM, Park JW, Kim SH, et al. Clinical evaluation of the computerized chronic urticaria-specific quality of life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol 2012;37:722–728.

19. Kim SH, Ahn J, Ock M, et al. The EQ-5D-5L valuation study in Korea. Qual Life Res 2016;25:1845–1852.

20. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210–216.

21. Health Insurance Review and Assessment Service. Medical statistics information [Internet]. Wonju (KR): Health Insurance Review and Assessment Service, 2022. [cited 2022 Jul 12]. Available from: https://opendata.hira.or.kr/home.do. 22. Health Insurance Review and Assessment Service. Medical service fee information [Internet]. Wonju (KR): Health Insurance Review and Assessment Service, 2022. [cited 2022 Jul 12]. Available from: https://www.hira.or.kr/. 23. X-rates. Translation rate information [Internet]. 2022. [cited 2022 Jul 12]. Available from: https://x-rates.com/. 24. Stull D, McBride D, Tian H, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol 2017;177:1093–1101.

25. Khalil S, McBride D, Gimenez-Arnau A, Grattan C, Balp MM, Stull DE. Weekly urticaria activity score (UAS7) and dermatology life quality index (DLQI) in validation of chronic spontaneous/idiopathic urticaria (CSU/CIU) health states. J Allergy Clin Immunol 2015;135:AB131.

26. Fricke J, Avila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy 2020;75:423–432.

27. Sussman G, Abuzakouk M, Berard F, et al. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy 2018;73:1724–1734.

28. Kocaturk E, Can PK, Akbas PE, et al. Management of chronic inducible urticaria according to the guidelines: a prospective controlled study. J Dermatol Sci 2017;87:60–69.

29. Kolkhir P, Bonnekoh H, Kocaturk E, et al. Management of urticarial vasculitis: a worldwide physician perspective. World Allergy Organ J 2020;13:100107.

30. Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019;49:655–662.

31. Choi WS, Lim ES, Ban GY, et al. Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria. Korean J Intern Med 2018;33:185–192.

32. Lee MS, Yoon J, Kim J, et al. Health-related utility of EQ-5D in Korean adults with chronic urticaria: mapping from urticaria outcome measures. Allergy Asthma Immunol Res 2020;12:599–607.

33. Alen Coutinho I, Regateiro FS, Fernandes RA, et al. Refractory chronic urticaria in adults: clinical characterization and predictors of severity. Allergy Asthma Clin Immunol 2020;16:97.

34. Lacour JP, Khemis A, Giordano-Labadie F, et al. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study). Eur J Dermatol 2018;28:795–802.